Venture Capital

Is Medtech Venture Capital Dead in the Water? Interview with Kevin Bitterman, Principal at Polaris Venture Partners

Is medtech venture capital like a rare, nearly extinct animal? You know, similar to one of those odd, but interesting animals we’ve all seen on the Discovery Channel? Like the Passenger Pigeon.

In fact, as recently as 200 years ago, Passenger Pigeons weren’t anywhere near extinction. They were actually the most common bird in North America. So what’s the parallel between the Passenger Pigeon and medtech venture capital? Answer: Scarcity!

VCs are becoming less and less interested in healthcare because of diminishing returns. With that said, will medtech venture capital eventually see the same fate as the Passenger Pigeon? Or is well-known VC Terry McGuire right in declaring that, “Darwin was an optimist”?

To help answer those questions and a host of others, enter Kevin Bitterman, Principal at Polaris Venture Partners. In this interview, we learn what medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success.

Interview Highlights with Kevin Bitterman

  • Will the IPO market for medtech companies ever open up again? Also, what requirements would make for an attractive IPO candidate?
  • Where do large medical device companies see the greatest opportunity for growth?
  • What questions should medtech startups have already answered before approaching a potential buyer?
  • In terms of a potential exit, what is more important for a medical device startup – clinical data or commercialization?
  • Besides venture capital, where else should medical device startups look for money?
  • What is Kevin’s personal medtech investment psychology?
  • After receiving his Ph.D. from Harvard Medical School, what attracted Kevin to the medtech venture capital space?
  • Kevin’s lasting advice for early-stage medical device companies.

Listen to the Interview with Kevin Bitterman

Read the Interview with Kevin Bitterman

Download a copy of the interview transcript right here.

More About Kevin Bitterman

Kevin Bitterman is a Principal at Polaris Venture Partners. Kevin joined Polaris in 2004 and focuses on investments in the life sciences.

Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases. Kevin has authored papers in several top tier journals, is an inventor on multiple patents, and is a co-founder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK).

Kevin currently represents Polaris as a Director of Biolex Therapeutics, EPacing Inc., Follica Inc., Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Taris Biomedical, and Visterra. Additionally, Kevin is a Board Observer to Pulmatrix Inc.

Prior to obtaining his Ph.D. at Harvard Medical School, Kevin earned a B.A. with highest honors from Rutgers College with a major in Biological Sciences and a minor in Philosophy.

You May Like These Articles

  • Recent
  • Featured
  • Related

Key Lessons for Developing an Insurance Coverage and Reimbursement Strategy: Interview with Mike Kujak, CEO of Francis Medical

In this interview with Mike Kujak, CEO of Francis Medical, he offers advice about navigating the early-stage medtech regulatory and reimbursement environments.

How to Position Your Medtech Start-Up for an Exit: Interview with Bruce Shook, CEO of Vesper Medical

In this conversation with Bruce Shook, CEO of Vesper Medical, we’ll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit.

The Most Important Piece of Advice for Raising Medtech Venture Capital: Interview with Sean Saint, Founder of Companion Medical

In this interview with Sean Saint, CEO of Companion Medical, we covered his journey from the inception of the InPen to their eventual exit to Medtronic.

How to Win with Contract Manufacturers: Interview with Travis Sessions, CEO of Biomerics

In this interview with Travis Sessions, CEO of Biomerics and Managing Partner of Med Venture Holdings, we discuss critical things to look for when identifying and working with contract manufacturers.

Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular

In this interview, Bruce Shook discusses medical device insurance coverage and reimbursement, as well as advice for other healthcare entrepreneurs that need to raise money.

Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger

In this interview, the legendary Dr. John Simpson shares what drew him to the field of cardiology, his approach to building a medtech team, and why knowing your strengths and limitations is key to making a difference in the lives of others.

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

In this interview with Duke Rohen, he discusses how he successfully led two early-stage medtech companies at the same time and the major lessons he learned raising money for 4 different medical device companies.

Having a Heart Attack? There’s an App for That! The Incredible Story of How Dr. David Albert Brought the ECG iPhone App to Market

In this interview with Dr. David Albert, we learn about his incredible journey in bringing the first iPhone ECG app to market with AliveCor.

Why Early Stage Medical Device Deals Aren’t as Bad as You May Think: Interview with Mike Carusi, General Partner at Lightstone Ventures

In this interview with medtech venture capitalist, Mike Carusi, he explains why early-stage medical device companies should look at biotech and pharma for creative ways to fund their companies.

Is Medtech Venture Capital Dead in the Water? Interview with Kevin Bitterman, Principal at Polaris Venture Partners

In this interview with Kevin Bitterman, we learn what medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success.

How to Fund Medtech Startups in a Capital-Efficient Manner: Interview with Rich Ferrari, Managing Director of De Novo Ventures

In this interview with Rich Ferrari of De Novo Ventures, we learn more about the current state of medtech venture capital and the impact on medical device startups.

What it Takes to Get a Medtech VC to Say Yes: Interview with Lisa Suennen

In this interview with Lisa Suennen, we learn why medical device companies will need to adjust their business models to succeed in today's healthcare environment.

Success! Your membership is now active.